Olanzapine for psychotic and behavioral disturbances in Alzheimer disease

Annals of Pharmacotherapy

Volumn 37, Issue 9, 2003, Pages 1321-1324

  Schatz, Robin A ^a,b  

^a UNIVERSITY OF TOLEDO   (United States)

^b NONE   (United States)

Author keywords

Alzheimer disease; Dementia; Olanzapine

Indexed keywords

BENZODIAZEPINE; HALOPERIDOL; LORAZEPAM; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

AKATHISIA; ALZHEIMER DISEASE; BEHAVIOR DISORDER; CLINICAL TRIAL; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; GAIT DISORDER; HUMAN; MEDLINE; META ANALYSIS; PARKINSONISM; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SIDE EFFECT; SOMNOLENCE; TARDIVE DYSKINESIA;

ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; HUMANS; MENTAL DISORDERS; PIRENZEPINE; PSYCHOTIC DISORDERS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0041422329     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D050     Document Type: Review

References (16)

1. Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JCS. Mental and behavioral disturbances in dementia: findings from the Cache County study on memory in aging. Am J Psychiatry 2000;157:708-14.
2. Levy ML, Cummings JL, Fairbanks LA, Bravi D, Calvani M, Carta A. Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer's disease. Am J Psychiatry 1996;153:1438-43.
3. Hake AM. The treatment of Alzheimer's disease: the approach from a clinical specialist in the trenches. Semin Neurol 2002;22:71-4.
4. Schneider LS, Pollock VE, Lyness SA. A metaanalysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 1990;38:553-63.
5. Devanand DP, Marder K, Michaels KS, Sackeim HA, Bell K, Sullivan MA, et al. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. Am J Psychiatry 1998;155:1512-20.
6. Kennedy JS, Bymaster FP, Schuh L, Calligaro DO. Nomikos G, Felder CC, et al. A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data. Int J Geriatr Psychiatry 2001;16(suppl 1):S33-61.
7. Satterlee WG, Reams SG. Burns PR. Hamilton S, Tran PV, Tollefson GD. A clinical update on olanzapine treatment in schizophrenia and in elderly Alzheimer's disease patients (abstract). Psychopharmacol Bull 1995;31:534.
8. Street JS, Clark S, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2000;57:968-76.
9. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994.
10. Kennedy JS, Zagar A, Bymaster F, Nomikos G, Trzepacz PT, Gilmore JA, et al. The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease. Int J Geriatr Psychiatry 2001:16(suppl 1):S24-32.
11. Mintzer J, Faison W, Street JS, Sutton VK, Breier A. Olanzapine in the treatment of anxiety symptoms due to Alzheimer's disease: a post hoc analysis. Int J Geriatr Psychiatry 2001;16(suppl 1):S71-7.
12. Clark WS, Street JS, Feldman PD, Breier A. The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease. J Clin Psychiatry 2001;62:34-40.
13. Street JS, Clark WS, Kadam DL, Mitan SJ, Juliar BE, Feldman PD, et al. Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia. Int J Geriatr Psychiatry 2001;16(suppl 1):S62-70.
14. Herz LR, Volicer L, Frankenburg F, Colon S, Kittur S. A 6-week, double-blind comparison of olanzapine, risperidone, and placebo for behavioral disturbances in Alzheimer's disease (abstract). J Clin Psychiatry 2002;63:1065.
15. Meehan KM, Wang H, David SR, Nisivoccia JR, Jones B, Beasley CM, et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology 2002;26:494-504.
16. Prescribing information. Zyprexa (olanzapine). Indianapolis: Eli Lilly and Company, 2002.